IL127581A - The crystalline form I of clarithromycin, its preparation, and the pharmaceutical compositions containing it - Google Patents

The crystalline form I of clarithromycin, its preparation, and the pharmaceutical compositions containing it

Info

Publication number
IL127581A
IL127581A IL12758197A IL12758197A IL127581A IL 127581 A IL127581 A IL 127581A IL 12758197 A IL12758197 A IL 12758197A IL 12758197 A IL12758197 A IL 12758197A IL 127581 A IL127581 A IL 127581A
Authority
IL
Israel
Prior art keywords
methylerythromycin
substantially free
preparation
peaks
powder
Prior art date
Application number
IL12758197A
Other languages
English (en)
Hebrew (he)
Other versions
IL127581A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24736505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL127581A0 publication Critical patent/IL127581A0/xx
Publication of IL127581A publication Critical patent/IL127581A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12758197A 1996-07-29 1997-07-25 The crystalline form I of clarithromycin, its preparation, and the pharmaceutical compositions containing it IL127581A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/681,723 US5858986A (en) 1996-07-29 1996-07-29 Crystal form I of clarithromycin
PCT/US1997/013128 WO1998004573A1 (en) 1996-07-29 1997-07-25 Crystal form i of clarithromycin

Publications (2)

Publication Number Publication Date
IL127581A0 IL127581A0 (en) 1999-10-28
IL127581A true IL127581A (en) 2004-06-20

Family

ID=24736505

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12758197A IL127581A (en) 1996-07-29 1997-07-25 The crystalline form I of clarithromycin, its preparation, and the pharmaceutical compositions containing it

Country Status (18)

Country Link
US (1) US5858986A (cs)
EP (1) EP0915898B1 (cs)
JP (2) JP2000515894A (cs)
KR (1) KR100498800B1 (cs)
CN (2) CN1754884A (cs)
AT (1) ATE255589T1 (cs)
AU (1) AU3739797A (cs)
BR (1) BR9710768A (cs)
CA (2) CA2258606C (cs)
CZ (1) CZ294446B6 (cs)
DE (1) DE69726577T2 (cs)
DK (1) DK0915898T3 (cs)
ES (1) ES2173056T3 (cs)
IL (1) IL127581A (cs)
NZ (1) NZ333380A (cs)
PT (1) PT915898E (cs)
TR (1) TR199900083T2 (cs)
WO (1) WO1998004573A1 (cs)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
AU4942800A (en) * 1999-06-11 2001-01-02 Ranbaxy Laboratories Limited Novel amorphous form of clarithromycin
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
WO2001044262A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
AU2261901A (en) 2000-01-11 2001-07-24 Teva Pharma Processes for preparing clarithromycin polymorphs
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
RU2230748C2 (ru) * 2000-03-15 2004-06-20 Ханми Фарм. Ко., Лтд. Способ получения кларитромицина в виде кристаллов формы ii
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
KR20000037126A (ko) * 2000-04-08 2000-07-05 김용규 6-메틸 에리스로마이신 ａ의 제조방법
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
MXPA03003146A (es) * 2000-10-13 2004-12-06 Advancis Pharmaceuticals Derivados de eritromicina de liberacion prolongada.
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
DE102007016367A1 (de) * 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
CN101525360B (zh) * 2008-03-06 2012-10-10 刘力 大环内酯类有机酸盐的水合物及其制备和用途
CN101812102B (zh) * 2009-02-21 2015-09-02 王凌峰 6-o-甲基红霉素a晶型v
CN102532222B (zh) * 2010-12-21 2015-06-17 北大方正集团有限公司 一种麦迪霉素的结晶方法
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN102942607A (zh) * 2012-11-28 2013-02-27 宁夏启元药业有限公司 一种复合溶剂结晶红霉素的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) * 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
EP0260938B1 (en) 1986-09-18 1992-12-09 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for preparing the same
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
JP2782793B2 (ja) * 1988-06-15 1998-08-06 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US5872229A (en) * 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives

Also Published As

Publication number Publication date
DE69726577D1 (en) 2004-01-15
CN1229411A (zh) 1999-09-22
DE69726577T2 (de) 2004-11-04
NZ333380A (en) 2000-01-28
CZ294446B6 (cs) 2005-01-12
JP2010090156A (ja) 2010-04-22
DK0915898T3 (da) 2004-02-16
AU3739797A (en) 1998-02-20
EP0915898B1 (en) 2003-12-03
CA2627035A1 (en) 1998-02-05
CN1754884A (zh) 2006-04-05
IL127581A0 (en) 1999-10-28
KR20000029644A (ko) 2000-05-25
CZ9999A3 (cs) 1999-05-12
PT915898E (pt) 2004-02-27
ATE255589T1 (de) 2003-12-15
CA2258606A1 (en) 1998-02-05
EP0915898A1 (en) 1999-05-19
BR9710768A (pt) 1999-08-17
US5858986A (en) 1999-01-12
CN1216892C (zh) 2005-08-31
CA2258606C (en) 2003-05-27
ES2173056T1 (es) 2002-10-16
ES2173056T3 (es) 2004-06-16
JP5290136B2 (ja) 2013-09-18
JP2000515894A (ja) 2000-11-28
TR199900083T2 (xx) 1999-04-21
WO1998004573A1 (en) 1998-02-05
KR100498800B1 (ko) 2005-07-01

Similar Documents

Publication Publication Date Title
US5858986A (en) Crystal form I of clarithromycin
US5844105A (en) Preparation of crystal form II of clarithromycin
AU2001222619C1 (en) Processes for preparing clarithromycin polymorphs
AU733646B2 (en) Preparation of crystal form II of clarithromycin
AU783055B2 (en) Processes for preparing clarithromycin polymorphs and novel polymorph IV
CA2309963C (en) 6-o-alkyl erythromycin b oxime
CA2386527C (en) Crystal form i of clarithromycin
AU777612B2 (en) Crystal form I of clarithromycin
CA2488397C (en) Crystal form ii of clarithromycin
CA2386534C (en) Crystal form ii of clarithromycin and uses thereof
HK1089182A (en) Crystal form i of clarithromycin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired